KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Resmed (RMD) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Resmed (RMD) over the last 17 years, with Q4 2025 value amounting to 34.56%.

  • Resmed's EBITDA Margin rose 20100.0% to 34.56% in Q4 2025 from the same period last year, while for Dec 2025 it was 33.7%, marking a year-over-year increase of 20300.0%. This contributed to the annual value of 34.92% for FY2025, which is 48500.0% up from last year.
  • According to the latest figures from Q4 2025, Resmed's EBITDA Margin is 34.56%, which was up 20100.0% from 33.43% recorded in Q3 2025.
  • Over the past 5 years, Resmed's EBITDA Margin peaked at 34.56% during Q4 2025, and registered a low of 23.66% during Q4 2023.
  • Moreover, its 5-year median value for EBITDA Margin was 28.99% (2021), whereas its average is 29.36%.
  • As far as peak fluctuations go, Resmed's EBITDA Margin crashed by -34500bps in 2023, and later soared by 88900bps in 2024.
  • Over the past 5 years, Resmed's EBITDA Margin (Quarter) stood at 27.79% in 2021, then decreased by -2bps to 27.1% in 2022, then fell by -13bps to 23.66% in 2023, then skyrocketed by 38bps to 32.54% in 2024, then rose by 6bps to 34.56% in 2025.
  • Its EBITDA Margin stands at 34.56% for Q4 2025, versus 33.43% for Q3 2025 and 33.72% for Q2 2025.